Amgen (AMG 337) Overview

  • Status
  • Acquired/​Merged

  • Latest Deal Type
  • Buyout/​LBO

  • Financing Rounds
  • 1

Amgen (AMG 337) General Information

Description

A mid-stage anticancer MET inhibitor drug. The compound is a phase 2 small molecule inhibitor of the cell surface enzyme which stimulates cancer cell scattering, invasion and protection from apoptosis. It is being developed to treat gastric and esophageal cancers.

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Corporate Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320
  • United States
Primary Industry
Buildings and Property
Other Industries
Pharmaceuticals
Acquirer
NantPharma
Vertical(s)
Life Sciences, Oncology
Corporate Office
  • One Amgen Center Drive
  • Thousand Oaks, CA 91320
  • United States

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Amgen (AMG 337) Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Amgen (AMG 337)‘s full profile, request access.

Request a free trial

Amgen (AMG 337) Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Amgen (AMG 337)‘s full profile, request access.

Request a free trial

Amgen (AMG 337) FAQs

  • Where is Amgen (AMG 337) headquartered?

    Amgen (AMG 337) is headquartered in Thousand Oaks, CA.

  • What industry is Amgen (AMG 337) in?

    Amgen (AMG 337)’s primary industry is Buildings and Property.

  • Is Amgen (AMG 337) a private or public company?

    Amgen (AMG 337) is a Private company.

  • What is Amgen (AMG 337)’s current revenue?

    The current revenue for Amgen (AMG 337) is .

  • Who are Amgen (AMG 337)’s investors?

    Amgen has invested in Amgen (AMG 337).

  • When was Amgen (AMG 337) acquired?

    Amgen (AMG 337) was acquired on 14-Sep-2015.

  • Who acquired Amgen (AMG 337)?

    Amgen (AMG 337) was acquired by NantPharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »